Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968543 | 0.84 | MTNR1A (0.44) | FFAR1SLC9A1MTNR1AMTNR1BP2RX7 | |
| SCHEMBL2957759 | 0.84 | MTNR1A (0.60) | FFAR1MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL2134742 | 0.82 | FFAR1 (0.47) | FFAR1MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL21921670 | 0.82 | FFAR1 (0.47) | FFAR1MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL2134746 | 0.82 | FFAR1 (0.47) | FFAR1MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL3418572 | 0.80 | FFAR1 (0.48) | FFAR1SLC9A1KMO | |
| SCHEMBL24738015 | 0.80 | SLC9A1 (0.64) | FFAR1SLC9A1MEN1KMT2AKMO | |
| SCHEMBL29302263 | 0.80 | SLC9A1 (0.64) | FFAR1SLC9A1MEN1KMT2AKMO | |
| SCHEMBL10288350 | 0.79 | FFAR1 (0.47) | FFAR1KMT2A | |
| SCHEMBL2133690 | 0.79 | FFAR1 (0.47) | FFAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763728-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-07-27 | — | — | US | disclosed |
| US-20090257977-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | PEKARI KLAUS | 2009-10-15 | — | — | US | disclosed |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257977-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, BCL2, CCAR2 | FFAR1 3410/4885SLC9A1 4724/4885MTNR1A 1374/4885 |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | FFAR1 3294/4885SLC9A1 4718/4885MTNR1A 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.